Efficacy of and Resistance to Rifaximin-based Quadruple Therapy in Helicobacter pylori Eradication

다국어 초록 (Multilingual Abstract)

Background/Aims: The treatment options for Helicobacter pylori (H. pylori) infection are in a state of flux: traditional triple therapies have started to fail, and new treatments are unable to achieve optimal eradication rates. Rifaximin and rifabutin are new antibiotics.
The aim of this study was to evaluate the efficacy and safety of adding rifaximin to the standard triple regimen and of a rifabutin- based triple regimen as a rescue therapy for H. pylori eradication.
Materials and Methods: We enrolled 27 H. pylori-positive patients who were treated with a proton pump inhibitor, amoxicillin, clarithromycin, and rifaximin for 14 days. H. pylori eradication was assessed by a 13C-urea breath test performed 4 weeks after therapy completion. The efficacy of the therapy was based on intention-to-treat (ITT) and per-protocol (PP) analysis. We also investigated the resistance rate, compliance, and side effects associated with rifaximin therapy. Minimal inhibitory concentrations and resistance to rifabutin were evaluated using the agar dilution method.
Results: Of the 27 patients, 22 completed the treatment protocol with 100% compliance; five patients withdrew. The ITT and PP eradication rates for the rifaximin-containing quadruple therapy were 70.4% (19/27) and 86.3% (19/22), respectively. Adverse events were observed in five of 22 patients (22.7%). The resistance rates to rifaximin and rifabutin were 66.7% (2/3) and 0% (0/3), respectively.
Conclusions: The findings of this study show the limitations of rifaximin-based quadruple therapy and suggest the benefits of a rifabutin- based rescue regimen in South Korea.

참고문헌 (Reference)

1 Qadri Q, "inflammation and gastric cancer" 45 : 126-132, 2014

2 Zhang RG, "Role of Helicobacter pylori infection in pathogenesis of gastric carcinoma" 7 : 97-107, 2016

3 Scarpignato C, "Rifaximin: a poorly absorbed antibiotic. Pharmacology and clinical use" Karger Medical and Scientific Publishers 2005

4 Gasbarrini A, "Rifaximin-based regimens for eradication of Helicobacter pylori : a pilot study" 24 : 195-200, 2006

5 Scarpignato C, "Rifaximin, a poorly absorbed antibiotic:pharmacology and clinical potential" 51 (51): 36-66, 2005

6 Vaira D, "Rifaximin suspension for the eradication of Helicobacter pylori" 58 : 300-308, 1997

7 Nizhevich AA, "Rifaximin in combined treatment of the Helicobacter pylori infection in childhood" 1 : 85-87, 2011

8 Lauritano EC, "Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth" 22 : 31-35, 2005

9 De Giorgio R, "Rifaximin and Helicobacter pylori eradication" 1 : 105-110, 1997

10 Jiang ZD, "Rifaximin : in vitro and in vivo antibacterial activity--a review" 51 (51): 67-72, 2005

11 Baker DE, "Rifaximin : a nonabsorbed oral antibiotic" 5 : 19-30, 2005

12 Lim HC, "Rifabutinbased high-dose proton-pump inhibitor and amoxicillin triple regimen as the rescue treatment for Helicobacter pylori" 19 : 455-461, 2014

13 Bock H, "Rifabutin-based triple therapy after failure of Helicobacter pylori eradication treatment : preliminary experience" 31 : 222-225, 2000

14 Canducci F, "Rifabutin-based Helicobacter pylori eradication ‘rescue therapy’" 15 : 143-, 2001

15 Perri F, "Rifabutin-based 'rescue therapy' for Helicobacter pylori infected patients after failure of standard regimens" 14 : 311-316, 2000

16 Gisbert JP, "Review article: the effectiveness of standard triple therapy for Helicobacter pylori has not changed over the last decade, but it is not good enough" 34 : 1255-1268, 2011

17 Mégraud F, "Review article : the treatment of refractory Helicobacter pylori infection" 17 : 1333-1343, 2003

18 Gabrielli M, "Re: “Chronic Helicobacter pylori infection and migraine: a case‐control study” (Pinessi L, Savi L, Pellicano R, et al. Headache. 2000;40:836‐839)" 42 : 236-237, 2002

19 Zhang YX, "Primary antibiotic resistance of Helicobacter pylori strains isolated from patients with dyspeptic symptoms in Beijing : a prospective serial study" 21 : 2786-2792, 2015

20 Yari F, "Loop-mediated isothermal amplification as a fast noninvasive method of Helicobacter pylori diagnosis" 30 : 464-470, 2016

21 Kim N, "Institutional difference of antibiotic resistance of Helicobacter pylori strains in Korea" 40 : 683-687, 2006

22 Mégraud F, "In vitro activity of rifaximin against Helicobacter pylori" 13 : 184-186, 1994

23 Franchini M, "Helicobacter pylori infection and immune thrombocytopenic purpura : an update" 9 : 342-346, 2004

24 Du LJ, "Helicobacter pylori eradication therapy for functional dyspepsia : systematic review and meta-analysis" 22 : 3486-3495, 2016

25 Candelli M, "Helicobacter pylori eradication and acne rosacea resolution : cause-effect or coincidence" 36 : 163-, 2004

26 Gasbarrini A, "Helicobacter pylori and extragastric diseases--other Helicobacters" 9 (9): 57-66, 2004

27 Quesada M, "Evaluation of Helicobacter pylori susceptibility to rifaximin" 27 : 393-396, 2004

28 최강현, "Efficacy of Levofloxacin and Rifaximin based Quadruple Therapy in Helicobacter pylori Associated Gastroduodenal Disease: A Double-Blind, Randomized Controlled Trial" 대한의학회 26 (26): 785-790, 2011

29 Pretolani S, "Effect of rifaximin, a new non-absorbed antibiotic, in the treatment of Helicobacter pylori infection" 56 : 144A-, 1993

30 Kim JM, "Distribution of antibiotic MICs for Helicobacter pylori strains over a 16-year period in patients from Seoul, South Korea" 48 : 4843-4847, 2004

31 Malfertheiner P, "Current concepts in the management of Helicobacter pylori infection : the Maastricht III Consensus Report" 56 : 772-781, 2007

32 Scarpignato C, "Clinical pharmacology and therapy of Helicobacter pylori infection. Vol. 11" Karger Publishers 87-127, 1999

33 Vázquez Romero M, "Chronic urticaria and Helicobacter pylori" 122 : 573-575, 2004

34 Gasbarrini A, "Association between Helicobacter pylori cytotoxic type I CagA-positive strains and migraine with aura" 20 : 561-565, 2000

35 Chey WD, "American College of Gastroenterology guideline on the management of Helicobacter pylori infection" 102 : 1808-1825, 2007

36 Houben MH, "A systematic review of Helicobacter pylori eradication therapy--the impact of antimicrobial resistance on eradication rates" 13 : 1047-1055, 1999

37 Dell’Anna A, "A randomized openly comparative study between rifaximin suspension versus rifaximin pills for the eradication of Helicobacter pylori" 3 : 105-110, 1999